Online citations, reference lists, and bibliographies.
← Back to Search

G3.5 PAMAM Dendrimers Enhance Transepithelial Transport Of SN38 While Minimizing Gastrointestinal Toxicity.

Deborah S. Goldberg, N. Vijayalakshmi, P. Swaan, H. Ghandehari
Published 2011 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Poly(amido amine) (PAMAM) dendrimers have shown promise in oral drug delivery. Conjugation of SN38 to PAMAM dendrimers has the potential to improve its oral absorption while minimizing gastrointestinal toxicity. In this work we evaluated G3.5 PAMAM dendrimer-SN38 conjugates with ester-linked glycine and β-alanine spacers for their suitability in oral therapy of hepatic colorectal cancer metastases. G3.5-βAlanine-SN38 was mostly stable while G3.5-Glycine-SN38 showed 10%, 20%, and 56% SN38 release in simulated gastric, intestinal and liver environments for up to 6, 24 and 48 hours, respectively. Short-term treatment of Caco-2 cells with G3.5-SN38 conjugates did not reduce cell viability, while comparable concentrations of SN38 caused significant cytotoxicity. G3.5-Glycine-SN38 and G3.5-βAlanine-SN38 showed IC₅₀ values of 0.60 and 3.59 μM, respectively, in HT-29 cells treated for 48 h, indicating the efficacy of the drug delivery system in colorectal cancer cells with longer incubation time. Both conjugates increased SN38 transepithelial transport compared to the free drug. Transport of G3.5-Glycine-SN38 was highly concentration-dependent whereas transport of G3.5-βAlanine-SN38 was concentration-independent, highlighting the influence of drug loading and spacer chemistry on transport mechanism. Together these results show that PAMAM dendrimers have the potential to improve the oral bioavailability of potent anti-cancer drugs.
This paper references
10.1007/s11095-006-9122-2
Transport of Poly(Amidoamine) Dendrimers across Caco-2 Cell Monolayers: Influence of Size, Charge and Fluorescent Labeling
Kelly M. Kitchens (2006)
10.1016/S0378-5173(99)00463-9
Polyamidoamine Starburst dendrimers as solubility enhancers.
O. M. Milhem (2000)
10.1093/ANNONC/MDM285
Effective oral chemotherapy for breast cancer: pillars of strength.
M. Findlay (2008)
10.1016/J.ADDR.2005.09.013
Transepithelial and endothelial transport of poly (amidoamine) dendrimers.
Kelly M. Kitchens (2005)
10.2307/4450450
A Spectrophotometric Assay Optimizing Conditions for Pepsin Activity.
E. E. Harding (1998)
10.1021/mp700089s
Endocytosis inhibitors prevent poly(amidoamine) dendrimer internalization and permeability across Caco-2 cells.
Kelly M. Kitchens (2008)
10.1016/S1056-8719(00)00107-6
Drug-like properties and the causes of poor solubility and poor permeability.
C. Lipinski (2000)
10.1021/TX015508+
Synthesis of new carboxylesterase inhibitors and evaluation of potency and water solubility.
C. Wheelock (2001)
10.1007/s11095-008-9572-9
Potential Oral Delivery of 7-Ethyl-10-Hydroxy-Camptothecin (SN-38) using Poly(amidoamine) Dendrimers
Rohit B. Kolhatkar (2008)
10.1038/nbt1171
Designing dendrimers for biological applications
C. C. Lee (2005)
10.1016/J.ADDR.2005.09.019
Dendrimer biocompatibility and toxicity.
R. Duncan (2005)
10.1634/THEONCOLOGIST.6-1-66
Irinotecan (CPT-11): recent developments and future directions--colorectal cancer and beyond.
M. Rothenberg (2001)
10.1021/bc700333s
Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers.
H. Zhao (2008)
10.1016/j.ijpharm.2009.05.069
The gastrointestinal stability of lipid nanocapsules.
E. Roger (2009)
10.1016/j.addr.2009.02.010
PEG conjugates in clinical development or use as anticancer agents: an overview.
G. Pasut (2009)
10.1016/J.JCONREL.2003.12.006
The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability.
A. D’Emanuele (2004)
10.1016/S0378-5173(03)00391-0
Transport mechanism(s) of poly (amidoamine) dendrimers across Caco-2 cell monolayers.
M. Elsayed (2003)
10.2165/00019053-199201040-00006
Potential Cost Savings of Oral Versus Intravenous Etoposide in the Treatment of Small Cell Lung Cancer
S. Pashko (2012)
10.1038/nrd1088
The dawning era of polymer therapeutics
R. Duncan (2003)
Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan.
G. Xu (2002)
10.1016/J.TIBTECH.2005.11.006
Polymer conjugates: nanosized medicines for treating cancer.
M. Vicent (2006)
10.1021/bc100094z
Carboxyl-terminated PAMAM-SN38 conjugates: synthesis, characterization, and in vitro evaluation.
N. Vijayalakshmi (2010)
10.1016/j.addr.2009.10.004
HPMA copolymers: origins, early developments, present, and future.
J. Kopeček (2010)
10.1021/JM9810809
Bisphosphonate prodrugs: synthesis and in vitro evaluation of novel clodronic acid dianhydrides as bioreversible prodrugs of clodronate.
M. Ahlmark (1999)
10.1200/JCO.2004.10.170
Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000.
S. Chang (2004)
10.1007/s002800050656
Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice
C. Stewart (1997)
10.1023/A:1007587523543
Anionic PAMAM Dendrimers Rapidly Cross Adult Rat Intestine In Vitro: A Potential Oral Delivery System?
R. Wiwattanapatapee (2004)
Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.
Y. Kawato (1991)
10.1007/s11095-010-0153-3
Cellular Entry of G3.5 Poly (amido amine) Dendrimers by Clathrin- and Dynamin-Dependent Endocytosis Promotes Tight Junctional Opening in Intestinal Epithelia
Deborah S. Goldberg (2010)
10.1007/s10198-006-0034-1
Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system
K. Le Lay (2006)
10.1007/978-3-642-00477-3_12
Improving oral delivery.
F. Gabor (2010)
10.1016/J.JCONREL.2004.03.022
Transport of dendrimer nanocarriers through epithelial cells via the transcellular route.
R. Jevprasesphant (2004)
10.1097/00001813-200106000-00003
Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells
W. Yamamoto (2001)
10.1042/BST0350061
Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging.
D. Tomalia (2007)
10.1016/j.jconrel.2009.04.022
Transepithelial transport of PEGylated anionic poly(amidoamine) dendrimers: implications for oral drug delivery.
D. Sweet (2009)
10.1021/mp9001206
Synthesis and in vivo antitumor efficacy of PEGylated poly(l-lysine) dendrimer-camptothecin conjugates.
Megan E Fox (2009)
10.1021/JF00048A062
PROTEOLYTIC AND PEPTIDOLYTIC ACTIVITIES IN COMMERCIAL PANCREATIN PROTEASE PREPARATIONS AND THEIR RELATIONSHIP TO SOME WHEY PROTEIN HYDROLYSATE CHARACTERISTICS
M. Mullally (1994)



This paper is referenced by
10.1016/j.addr.2011.09.010
Transepithelial transport and toxicity of PAMAM dendrimers: implications for oral drug delivery.
S. Sadekar (2012)
10.18632/ONCOSCIENCE.150
Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer
I. M. Montagner (2015)
10.1002/mabi.201500225
Regional Morphology and Transport of PAMAM Dendrimers Across Isolated Rat Intestinal Tissue.
Dallin Hubbard (2015)
10.1002/cmdc.201100456
RAFT‐Derived Polymer–Drug Conjugates: Poly(hydroxypropyl methacrylamide) (HPMA)–7‐Ethyl‐10‐hydroxycamptothecin (SN‐38) Conjugates
C. C. Williams (2012)
10.1016/j.ejps.2016.11.025
Comparison of 2 strategies to enhance pyridoclax solubility: Nanoemulsion delivery system versus salt synthesis
A. Groo (2017)
10.1016/j.ejps.2019.05.019
Nanoparticulate delivery of irinotecan active metabolite (SN38) in murine colorectal carcinoma through conjugation to poly (2-ethyl 2-oxazoline)-b-poly (L-glutamic acid) double hydrophilic copolymer.
M. Salmanpour (2019)
10.1155/2014/507273
Applications of dendrimers in drug delivery agents, diagnosis, therapy, and detection
B. Noriega-Luna (2014)
10.1016/j.ejpb.2013.01.019
Charge affects the oral toxicity of poly(amidoamine) dendrimers.
G. Thiagarajan (2013)
10.1007/s11095-014-1338-y
Intracellular Ca2+ Release Mediates Cationic but Not Anionic Poly(amidoamine) (PAMAM) Dendrimer-Induced Tight Junction Modulation
Brittany R. Avaritt (2014)
10.1007/978-981-15-2017-4_13
Nanotechnology Applications in Gastric Cancer
Begum Dariya (2020)
10.1016/j.ejpb.2016.05.021
Facilitating gastrointestinal solubilisation and enhanced oral absorption of SN38 using a molecularly complexed silica-lipid hybrid delivery system.
V. Bala (2016)
10.1016/j.ijpharm.2013.07.071
Poly(amido amine) dendrimers as absorption enhancers for oral delivery of camptothecin.
S. Sadekar (2013)
10.1002/9781118736449.CH13
Dendrimers in Biology and Nanomedicine
Jørn Bolstad Christensen (2013)
10.1007/978-981-15-2017-4
Theranostics Approaches to Gastric and Colon Cancer
S. R. Raju (2020)
10.1002/wnan.1409
Dendrimer-based nanocarriers: a versatile platform for drug delivery.
Hao-jui Hsu (2017)
10.7150/thno.49670
Ultrasound-triggered therapeutic microbubbles enhance the efficacy of cytotoxic drugs by increasing circulation and tumor drug accumulation and limiting bioavailability and toxicity in normal tissues
N. Ingram (2020)
10.1016/J.NANTOD.2014.04.008
Challenges associated with Penetration of Nanoparticles across Cell and Tissue Barriers: A Review of Current Status and Future Prospects.
Sutapa Barua (2014)
10.2174/1389200211309010028
Improving oral absorption via drug-loaded nanocarriers: absorption mechanisms, intestinal models and rational fabrication.
M. Shahbazi (2013)
10.22270/UJPR.V2I3.RW5
DENDRIMERS: A NOVEL TOOL FOR DRUG DELIVERY AND TARGETING
Udokwu Japhet Chigbo (2017)
Drug Delivery and Pharmacokinetics 3 . 1 Drug Delivery
(2017)
10.1142/S1793292011002871
NANOTECHNOLOGY IN PHARMACEUTICAL AND BIOMEDICAL APPLICATIONS: DENDRIMERS
P. Szymański (2011)
10.15272/AJBPS.V4I28.427
Nanotechnology: A possible healer in drug delivery system
Moniruzzaman (2014)
10.3109/02652048.2013.814727
Cytotoxicity and in vitro characterization studies of synthesized Jeffamine-cored PAMAM dendrimers
K. Öztürk (2014)
10.3892/MCO.2014.470
Advances in the application of nanotechnology in the diagnosis and treatment of gastrointestinal tumors.
B. Sun (2015)
10.1080/21691401.2018.1446969
CD133-targeted delivery of self-assembled PEGylated carboxymethylcellulose-SN38 nanoparticles to colorectal cancer
Mona Alibolandi (2018)
10.1039/C3NJ00300K
Dendrimers as macromolecular tools to tackle from colon to brain tumor types: a concise overview
S. Mignani (2013)
10.1007/978-1-4614-2140-5_15
What Can Nanomedicine Learn from the Current Developments of Nanotechnology
Sirikanya Chokaouychai (2014)
10.3109/10717544.2014.910564
Evaluation of polyamidoamine dendrimers as potential carriers for quercetin, a versatile flavonoid
Kanika Madaan (2016)
Chapter V Nanoformulations for Overcoming Poor Solubility
(2017)
10.1016/B978-0-323-47720-8.00010-9
Oral drug delivery potential of dendrimers
A. Singh (2017)
10.1021/acs.molpharmaceut.5b00785
Lipophilic Prodrugs of SN38: Synthesis and in Vitro Characterization toward Oral Chemotherapy.
V. Bala (2016)
10.1142/9789814520652_0022
Nanopreparations for Oral Administration
D. Hubbard (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar